mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
Status:
Recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
This is a prospective, one-arm, phase II clinical study of intravenous mFOLFOX6 plus
Camrelizumab combined with apatinib for CNLC stage III hepatocellular carcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University